ClinicalTrials.gg
Status unknownNCT03179527Updated Jun 7, 2017

Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina.

A Phase 4 interventional study of Anti-Platelet Drugs and Lipid Regulating Drugs in Unstable Angina, sponsored by Jun Li. Status unknown. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Jun Li · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Study summary

This study evaluates the clinical efficacy of Shuanghe Decoction in the treatment of unstable angina. All of the patients will be divided into 2 arms randomly. One of the arms will be treated by conventional western medicine, and the other one will be treated by Shuanghe Decoction at the base of conventional western medicine.

Read the detailed description

Shuanghe Decoction has the function of supplementing Qi and activating blood circulation, which will be used to treat patients with Qi deficiency and blood stasis syndrome.

02

Conditions studied

  • Unstable Angina

Browse trials for

Keywords

  • Unstable Angina
  • Shuanghe Decoction
03

In context

Angina, Unstable

331 studies on the registry are indexed under Angina, Unstable; 45 are open to participants now.

This study's planned enrollment of 120 is below the median of 212 across 201 interventional studies indexed under Angina, Unstable.

Browse Angina, Unstable studies →

Lead sponsor

Jun Li is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with coronary heart disease through coronary angiography or coronary CTA;

Patients have at least one of these symptoms:

  1. The stability of the nature of angina pectoris changes, that is, frequent attacks of angina pectoris, serious degree and prolonged duration;
  2. Angina pectoris during rest;
  3. The recent occurrence of angina pectoris caused by mild physical activity in the last month.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with stable angina; Patients with acute myocardial infarction; Chest pain caused by congenital heart disease, valvular heart disease, severe neurosis or arrhythmia; The heart function grade is III or IV; Patients with acute cerebral infarction; Patients complicated with other serious primary diseases; Patients with acute infection in recent 2 weeks; Uncontrolled hypertension (the resting blood pressure >160/95mmHg within one week); Diabetics emerged with serious diabetic complications; Patients can't finish the questionnaire due to abnormal mental and nervous or mental disorders; Pregnant or lactating women.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Qi deficiency and blood stasis

    Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.

    Drug: Anti-Platelet Drugs · Drug: Lipid Regulating Drugs · Drug: Coronary Vasodilator · Drug: Shuanghe Decoction

  • Other
    Conventional western medicine

    Patients in this group will be treated by conventional western medicine, including anti-platelet drugss,lipid regulating drugs, coronary vasodilator, etc.

    Drug: Anti-Platelet Drugs · Drug: Lipid Regulating Drugs · Drug: Coronary Vasodilator

Interventions

  • DrugAnti-Platelet Drugs

    Including aspirin and clopidogrel, etc

  • DrugLipid Regulating Drugs

    Mainly including statins

  • DrugCoronary Vasodilator

    Mainly including nitrates

  • DrugShuanghe Decoction

    Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.

06

What researchers measure

Primary outcomes

  1. Mortality

    Death caused by cardiovascular disease

    Time frame: Six months after drug intervention

Secondary outcomes

  1. Myocardial enzymes

    The unit is mmol/L

    Time frame: At baseline and 4 weeks after drug intervention

  2. Blood lipid

    The unit is mmol/L

    Time frame: At baseline and 4 weeks after drug intervention

  3. Treadmill exercise test

    The result will be positive or negative

    Time frame: At baseline and 4 weeks after drug intervention

  4. The incidence of myocardial infarction or heart failure

    Time frame: Six months after drug intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Wang J, Yu G. A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling. Evid Based Complement Alternat Med. 2013;2013:510208. doi: 10.1155/2013/510208. Epub 2013 May 14. PubMed 23762142 ↗
  • Yi GZ, Qiu YQ, Xiao Y, Yuan LX. The usefulness of xuefu zhuyu tang for patients with angina pectoris: a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2014;2014:521602. doi: 10.1155/2014/521602. Epub 2014 Aug 31. PubMed 25254054 ↗
  • Qiu Y, Xu H, Shi D. Traditional chinese herbal products for coronary heart disease: an overview of cochrane reviews. Evid Based Complement Alternat Med. 2012;2012:417387. doi: 10.1155/2012/417387. Epub 2012 Mar 28. PubMed 22536282 ↗
  • Liu W, Xiong X, Yang X, Chu F, Liu H. The Effect of Chinese Herbal Medicine Gualouxiebaibanxia Decoction for the Treatment of Angina Pectoris: A Systematic Review. Evid Based Complement Alternat Med. 2016;2016:8565907. doi: 10.1155/2016/8565907. Epub 2016 Sep 29. PubMed 27777598 ↗
  • Wang J, Yang X, Chu F, Chen J, He Q, Yao K, Teng F, Gao Y, Xing Y, Wu A, Xing Y. The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial. Evid Based Complement Alternat Med. 2013;2013:896467. doi: 10.1155/2013/896467. Epub 2013 May 8. PubMed 23737852 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2017; primary completion for Oct 2019, 27 months later.

Of 17 phase 4 interventional studies under Angina, Unstable, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 51. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jun 7, 2017
StartEst.
Jul 2017
Primary completionEst.
Oct 2019
CompletionEst.
Dec 2019
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03179527
Lead sponsor
Jun Li
Responsible party
Jun Li (Chief Physician, Guang'anmen Hospital of China Academy of Chinese Medical Sciences) — Sponsor-investigator
First posted
Jun 7, 2017
Start date
Jul 2017 (estimated)
Primary completion
Oct 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Jun 7, 2017

Study contacts

Panpan Tian
Contact
15652388175@163.com
+86 15652388175
Jun Li, MD
study director · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion